The Chinese Institute of Biological Products, a Chinese Biological Wuhan Biological Products under the China Medicine Group, announced that it has successfully separated monkey acne virus strains from the clinical samples of infected patients, and started research on vaccine drugs.
According to the "official WeChat public WeChat public account on Thursday (October 20), the Wuhan Institute of Biological Products Research has recently successfully separated monkey acne virus strains from the clinical samples of infected patients to help the epidemic of the monkey acne epidemicAll scientific research on prevention and control.
Sources said that monkey acne is a viral human beast caused by monkey acne virus infection. The clinical manifestations are mainly fever, rash, and lymph nodes.With West Africa, it has now become the most important acne virus in the field of public health.
Public information shows that the vaccine of the extinct smallpox virus (Smallpox) also has a certain prevention effect on monkey acne. Among them, Jynneos, a ceiling vaccine developed by Danish Bavarian Nordic, is currently the only approved monkey acne.vaccine.However, the World Health Organization said that only high -risk groups (such as those who are closely in contact with patients with acne) should consider vaccination, and it is not recommended for large -scale vaccines.
The World Health Organization announced on July 23 that the epidemic of monkey acne epidemic constitutes "international concerns of emergencies."As of October 19, a total of 7,5141 cases of infection were reported around the world, and more than 100 countries had found monkey acne cases.
As of now, mainland China has not notified the case of monkey acne infection, and Chongqing City has noticed the first diagnosis of overseas acne cases on September 16.
